Intrinsic asthma

Summary

Intrinsic asthma (MONDO:0004765) is a disease and 4 clinical trials. Top therapeutic interventions include levocetirizine. A subtype of asthma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	intrinsic asthma
Mondo ID	MONDO:0004765
DOID	DOID:9360
SNOMED CT	266361008
UMLS	C0155880
MedGen	510123
Is cancer (heuristic)	no

Also known as: non-allergic asthma

Disease family

This is a subtype of asthma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › lower respiratory tract disorder › bronchial disorder › asthma › intrinsic asthma

Related subtypes (7): cough variant asthma, status asthmaticus, allergic asthma, childhood onset asthma, occupational asthma, chronic asthma, acute asthma

Subtypes (3): environmental induced asthma, exercise-induced bronchoconstriction, aspirin-induced respiratory disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2
PHASE2/PHASE3	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01392859	PHASE2/PHASE3	COMPLETED	Characterization of the Role of Histamine in Children With Asthma
NCT01536522	EARLY_PHASE1	ENROLLING_BY_INVITATION	Asthma Inflammation Research
NCT05431920	Not specified	ACTIVE_NOT_RECRUITING	Effects of Vitamin D Supplementation in Adolescents With Asthma, Obesity and Vitamin D Deficiency.
NCT01144910	Not specified	WITHDRAWN	The Long-term Prognosis of Moderate to Severe Bronchial Hyperresponsiveness (BHR) in Asthmatic Preschool Children

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LEVOCETIRIZINE	4	1